TRBV3 Inhibitors
TRBV3 inhibitors are a class of chemical compounds designed to selectively interact with the T-cell receptor (TCR) β variable region 3 (TRBV3). This region is a part of the broader variable domain of the TCR complex, which plays a pivotal role in recognizing antigen peptides presented by major histocompatibility complex (MHC) molecules. The TRBV3 family includes a subset of TCRs that contribute to the specificity and diversity of T-cell responses, particularly in relation to antigen recognition. Inhibition of TRBV3 can be achieved through small molecules, peptides, or antibodies that block the interaction between TCRs bearing the TRBV3 sequence and their respective ligands. These inhibitors work by modulating the affinity or stability of this interaction, affecting downstream signaling pathways involved in T-cell activation and function.
The inhibition of TRBV3 can result in significant alterations to immune cell signaling, given the central role of TCRs in initiating adaptive immune responses. The inhibitors target specific signaling cascades, such as those involving ZAP-70, LAT, and other adaptor proteins that are critical for TCR-mediated signal transduction. This modulation can impact cellular activities like proliferation, cytokine production, and cytotoxic activity. Moreover, the specificity of these inhibitors for the TRBV3 region minimizes potential off-target effects on other TCR variable regions, which could otherwise disrupt a broader range of immune responses. Understanding the molecular structure and binding dynamics of TRBV3 inhibitors is crucial for designing compounds with high selectivity and affinity, ensuring precise modulation of T-cell receptor function without affecting unrelated immune processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
R788 inhibits TRBV3 expression by selectively targeting spleen tyrosine kinase (SYK), an enzyme involved in immune cell signaling, ultimately affecting T cell activation and the subsequent expression of TRBV3. | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
Ceritinib inhibits TRBV3 expression by targeting anaplastic lymphoma kinase (ALK), which has been implicated in T cell activation and immune response, ultimately leading to the downregulation of TRBV3 expression. | ||||||
Hypoxia inducible factor-1α inhibitor | 934593-90-5 | sc-205346 sc-205346A sc-205346B sc-205346C | 1 mg 5 mg 10 mg 25 mg | $32.00 $112.00 $190.00 $403.00 | 40 | |
R406 inhibits TRBV3 expression by selectively inhibiting spleen tyrosine kinase (SYK), a key enzyme involved in immune cell signaling, ultimately affecting T cell activation and the subsequent expression of TRBV3. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib inhibits TRBV3 expression by targeting receptor tyrosine kinases (RTKs) involved in immune cell signaling pathways, ultimately affecting T cell activation and the subsequent expression of TRBV3. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Afatinib inhibits TRBV3 expression by targeting epidermal growth factor receptor (EGFR), a receptor tyrosine kinase implicated in T cell function and immune response, ultimately leading to the downregulation of TRBV3 expression. | ||||||
Entrectinib | 1108743-60-7 | sc-507438 | 5 mg | $180.00 | ||
Entrectinib inhibits TRBV3 expression by targeting tropomyosin receptor kinases (TRKs), which play a role in T cell activation and immune response, ultimately affecting the expression of TRBV3. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib inhibits TRBV3 expression by targeting receptor tyrosine kinases (RTKs) involved in immune cell signaling pathways, ultimately affecting T cell activation and the subsequent expression of TRBV3. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Cabozantinib inhibits TRBV3 expression by targeting receptor tyrosine kinases (RTKs) involved in immune cell signaling pathways, ultimately affecting T cell activation and the subsequent expression of TRBV3. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Nintedanib inhibits TRBV3 expression by targeting receptor tyrosine kinases (RTKs) involved in immune cell signaling pathways, ultimately affecting T cell activation and the subsequent expression of TRBV3. | ||||||